durvalumab

1. 02:42
   ESMO 2026 现场信号

   #ScienceLink #Madrid2026 #ESMO26 #DUOE #CancerDeEndometrio
2. 01:36
   ESMO 2026 现场信号

   Interim OS data from the Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study at #ESMO26 show CP + durvalumab, followed by durvalumab with or without olaparib, was favored compared with CP alon
3. 01:32
   ESMO 2026 现场信号

   💡#ESMO26 I Durvalumab más enfortumab vedotin reduce un 42% el riesgo de muerte en cáncer de vejiga músculo-invasivo no candidato a cisplatino. @myesmo. https://www.diariomedico.com
4. 01:27
   ESMO 2026 现场信号

   A new SoC in extensive disease small cell lung cancer: Durvalumab plus Tarlatamab. 79% patients alive at 1 year. #ESMO26 #LungCancer @myESMO @_SEOM @gecp_org
5. 01:19
   ESMO 2026 现场信号

   In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative #durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1
6. 00:53
   ESMO 2026 现场信号

   💡#ESMO26 I Durvalumab más enfortumab vedotin reduce un 42% el riesgo de muerte en cáncer de vejiga músculo-invasivo no candidato a cisplatino. @myesmo. https://www.diariomedico.com

1. 23:35
   ESMO 2026 现场信号

   A new milestone for peri-op MIBC at #ESMO26 ! Durvalumab w/ or w/o tremelimumab in combination with EV (only adjuvant) improved survival outcomes!
2. 23:33
   ESMO 2026 现场信号

   3 dose of EV plus Durvalumab should be new SOC for this set of pts . Less is more . @myESMO @OncoAlert #esmo26 @tompowles1
3. 23:20
   ESMO 2026 现场信号

   #ESMO26, presentati in una sessione Proffered Paper del Presidential Symposium I i risultati di uno studio di Fase III sul #tumoredellavescica muscolo-invasivo: https://www.medinew
4. 23:20
   ESMO 2026 现场信号

   Novità sul trattamento del #tumoredellavescica muscolo-invasivo da #ESMO26.
5. 21:07
   ESMO 2026 现场信号

   Phase 3 DUO-E results show that adding durvalumab and olaparib to treatment extended median overall survival by 11.5 months for patients with advanced or recurrent endometrial canc
6. 19:23
   ESMO 2026 现场信号

   #ESMO26 Can molecular profiling identify who benefits most from perioperative durvalumab in MIBC?
7. 18:02
   ESMO 2026 现场信号

   #ESMO26 🇪🇸 | POP-DURVA Phase II
8. 17:27
   ESMO 2026 现场信号

   NIAGARA biomarker analysis at #ESMO26
9. 16:07
   ESMO 2026 现场信号

   POP-Durva | #ESMO26
10. 15:51
    ESMO 2026 现场信号

    Great presentation about translational analysis in durvalumab response in TNBC by Joana Ribeiro at #ESMO2026
11. 15:44
    ESMO 2026 现场信号

    ESMO 2026 | Does immune activation translate into tumor eradication?
12. 15:39
    ESMO 2026 现场信号

    🔹In POP-Durva, analyses on paired biopsies show immmune activation after 2 administrations of durvalumab in stage 1 TNBC
13. 15:34
    ESMO 2026 现场信号

    📌 Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
14. 15:32
    ESMO 2026 现场信号

    Oral abstract #BreastCancer session at #ESMO26: use pre-operative #durvalumab without chemotherapy in patients with cT1 cN0 triple-negative disease
15. 15:32
    ESMO 2026 现场信号

    POP-DURVA
16. 15:32
    ESMO 2026 现场信号

    #ESMO26 | POP-DURVA – Phase II
17. 06:35
    ESMO 2026 现场信号

    #ESMO26 | POP-DURVA

1. 02:42
   临床试验登记

   Zolbetuximab联合Durvalumab及FLOT方案用于CLDN18.2阳性胃癌或胃食管交界腺癌的新辅助化疗

   日本国立癌症中心启动2期试验（NCT07872722），计划入组29例CLDN18.2阳性局部进展期胃癌或胃食管交界腺癌患者，评估Zolbetuximab联合Durvalumab及FLOT方案新辅助化疗的疗效。主要终点为手术标本的组织学完全缓解率（Grade 3），关键次要终点包括不良事件发生率、治疗完成率及R0切除率。

当前热度 145·可比范围峰值 183（10月25日 03:00）·近 24 小时可比范围变化 –·当前参与者 22

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。